Related Experiment Videos
Custom-tailored drug immunoconjugates in cancer therapy
1Biological Therapy Institute, Franklin, Tennessee 37065-1700.
Molecular Biotherapy
|September 1, 1991
Summary
This study shows that individually tailored drug-antibody conjugates can be made for cancer patients. While feasible, drug release and patient immune responses present challenges for targeted cancer therapy.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Disseminated refractory malignancies pose significant treatment challenges.
- Targeted drug delivery aims to improve efficacy and reduce toxicity in cancer therapy.
Purpose of the Study:
- To assess the feasibility of preparing and administering individually specified drug-immunoconjugate cocktails for patients with refractory malignancies.
- To evaluate the safety, tolerability, and preliminary efficacy of these novel targeted therapies.
Main Methods:
- Forty-three patients received Adriamycin or mitomycin-C conjugated to monoclonal antibody (mAb) cocktails selected by >80% tumor cell binding.
- Immunohistochemistry and flow cytometry were used for cancer typing and antibody selection.
- Drug conjugates were administered intravenously after safety testing.
Main Results:
- Adriamycin immunoconjugates were generally well tolerated, but unpredictable hemopoietic depression occurred due to variable drug dissociation.
- Mitomycin-C conjugates showed dose-limiting thrombocytopenia.
- Serological evidence suggested anti-mouse mAb antibodies could predict clinical reactions.
- Limited patient responses were observed, including regression of lymph nodes and shrinkage of skin and tongue lesions.
Conclusions:
- Individually specified drug-immunoconjugate cocktails are feasible for refractory malignancies.
- Optimizing drug conjugation methods and managing drug release are critical hurdles for effective targeted cancer therapy.
- Further research is needed to overcome technical challenges and improve therapeutic outcomes.